1. Home
  2. CVKD vs AAME Comparison

CVKD vs AAME Comparison

Compare CVKD & AAME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CVKD
  • AAME
  • Stock Information
  • Founded
  • CVKD 2022
  • AAME 1968
  • Country
  • CVKD United States
  • AAME United States
  • Employees
  • CVKD N/A
  • AAME N/A
  • Industry
  • CVKD Medicinal Chemicals and Botanical Products
  • AAME Life Insurance
  • Sector
  • CVKD Health Care
  • AAME Finance
  • Exchange
  • CVKD Nasdaq
  • AAME Nasdaq
  • Market Cap
  • CVKD 34.2M
  • AAME 31.4M
  • IPO Year
  • CVKD 2023
  • AAME N/A
  • Fundamental
  • Price
  • CVKD $17.77
  • AAME $1.45
  • Analyst Decision
  • CVKD Strong Buy
  • AAME
  • Analyst Count
  • CVKD 1
  • AAME 0
  • Target Price
  • CVKD $32.00
  • AAME N/A
  • AVG Volume (30 Days)
  • CVKD 44.3K
  • AAME 2.4K
  • Earning Date
  • CVKD 05-08-2025
  • AAME 03-31-2025
  • Dividend Yield
  • CVKD N/A
  • AAME 2.76%
  • EPS Growth
  • CVKD N/A
  • AAME N/A
  • EPS
  • CVKD N/A
  • AAME N/A
  • Revenue
  • CVKD N/A
  • AAME $185,929,000.00
  • Revenue This Year
  • CVKD N/A
  • AAME N/A
  • Revenue Next Year
  • CVKD N/A
  • AAME N/A
  • P/E Ratio
  • CVKD N/A
  • AAME N/A
  • Revenue Growth
  • CVKD N/A
  • AAME 0.35
  • 52 Week Low
  • CVKD $5.40
  • AAME $1.26
  • 52 Week High
  • CVKD $22.90
  • AAME $2.95
  • Technical
  • Relative Strength Index (RSI)
  • CVKD 49.27
  • AAME 42.16
  • Support Level
  • CVKD $14.64
  • AAME $1.35
  • Resistance Level
  • CVKD $17.58
  • AAME $1.60
  • Average True Range (ATR)
  • CVKD 1.86
  • AAME 0.07
  • MACD
  • CVKD -0.29
  • AAME -0.01
  • Stochastic Oscillator
  • CVKD 39.10
  • AAME 34.48

About CVKD Cadrenal Therapeutics Inc.

Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.

About AAME Atlantic American Corporation

Atlantic American Corp operates in specialty markets within the life and health and property and casualty insurance industries. The company has two segments: American Southern, It provides property and casualty insurance including bodily injury and property damage liability coverage, uninsured motorist coverage, and physical damage coverage for commercial accounts. It also provides tailored business automobile insurance coverage, on a multi-year contract basis, to state governments and local municipalities, and Bankers Fidelity, the company's life and health operations offer a variety of life and supplemental health products including ordinary and term life insurance, Medicare supplement, and other health insurance. It earns revenue from the collection of premiums and investment income.

Share on Social Networks: